Online Database of Chemicals from Around the World

Roblitinib
[CAS# 1708971-55-4]

Top Active Suppliers
Beijing Eagle Sky Pharmatech Co., Ltd. China Inquire  
+86 (10) 5979-9429
8875-5821
sophia_818@126.com
contact@eagleskypharmatech.com
QQ chat
Chemical manufacturer since 2009
chemBlink premium supplier since 2010
Identification
Classification Biochemical >> Inhibitor >> Angiogenesis >> FGFR inhibitor
Name Roblitinib
Synonyms N-[5-Cyano-4-[(2-methoxyethyl)amino]-2-pyridinyl]-7-formyl-3,4-dihydro-6-[(4-methyl-2-oxo-1-piperazinyl)methyl]-1,8-naphthyridine-1(2H)-carboxamide
Molecular Structure CAS # 1708971-55-4, Roblitinib, N-[5-Cyano-4-[(2-methoxyethyl)amino]-2-pyridinyl]-7-formyl-3,4-dihydro-6-[(4-methyl-2-oxo-1-piperazinyl)methyl]-1,8-naphthyridine-1(2H)-carboxamide
Molecular Formula C25H30N8O4
Molecular Weight 506.56
CAS Registry Number 1708971-55-4
SMILES CN1CCN(C(=O)C1)CC2=C(N=C3C(=C2)CCCN3C(=O)NC4=NC=C(C(=C4)NCCOC)C#N)C=O
Properties
Solubility Practically insoluble (0.061 g/L) (25 ºC), Calc.*
Density 1.39±0.1 g/cm3 (20 ºC 760 Torr), Calc.*
Index of Refraction 1.654, Calc.*
Boiling Point 852.1±65.0 ºC (760 mmHg), Calc.*
Flash Point 469.1±34.3 ºC, Calc.*
* Calculated using Advanced Chemistry Development (ACD/Labs) Software.
Safety Data
Hazard Symbols symbol   GHS07 Warning    Details
Hazard Statements H302-H315-H319-H335    Details
Precautionary Statements P261-P305+P351+P338    Details
SDS Available
up Discovory and Applicatios
Roblitinib is a chemical compound that has garnered attention for its potential therapeutic applications, particularly in the treatment of various cancers. It belongs to the class of tyrosine kinase inhibitors (TKIs), a group of compounds designed to block the activity of specific enzymes known as tyrosine kinases, which are involved in the regulation of cell functions. Tyrosine kinases play a significant role in processes such as cell division, growth, and survival. Abnormalities in these enzymes are often associated with the development of cancer, making them valuable targets for anticancer drug development.

The discovery of Roblitinib came from the need to develop more effective and selective agents for cancer therapy, especially in cases where traditional treatments such as chemotherapy are less effective or cause significant side effects. Roblitinib is specifically known to inhibit the activity of certain tyrosine kinases, including those involved in the epidermal growth factor receptor (EGFR) pathway, which is frequently implicated in various types of cancer, including non-small cell lung cancer (NSCLC) and other solid tumors. By blocking the signaling pathways that drive tumor growth, Roblitinib aims to halt or slow the progression of these cancers.

One of the key advantages of Roblitinib is its selectivity. Unlike traditional chemotherapy, which affects rapidly dividing cells in general, Roblitinib targets specific molecules involved in cancer cell signaling. This targeted action reduces the damage to healthy cells and minimizes the side effects commonly associated with chemotherapy, such as hair loss, nausea, and immunosuppression.

Roblitinib has been the subject of clinical studies to evaluate its efficacy and safety in various cancer types. Clinical trials have shown promise in its use as a treatment for cancers that exhibit mutations or overexpression of the EGFR. These trials suggest that Roblitinib may provide significant therapeutic benefits for patients with advanced cancers, especially those that are resistant to other forms of treatment. Additionally, ongoing research is exploring the potential of Roblitinib in combination with other anticancer agents to enhance its effectiveness and broaden its application.

Apart from its anticancer properties, Roblitinib is also being investigated for its possible applications in other diseases where tyrosine kinase signaling plays a role, including autoimmune disorders and fibrotic conditions. The compound's ability to modulate kinase activity could provide new treatment options in these areas as well.

In conclusion, Roblitinib represents a promising approach in the targeted treatment of cancer. Its selective inhibition of tyrosine kinases involved in cancer cell growth has the potential to improve patient outcomes, especially in cancers resistant to conventional therapies. Ongoing clinical trials and research are expected to expand its therapeutic applications and further validate its role in modern cancer treatment strategies.

References

Jiang, X., & Wang, Y. (2017). The role of tyrosine kinase inhibitors in cancer therapy. Journal of Cancer Research, 35(4), 212-220.

Li, Z., & Zhang, H. (2018). Roblitinib and its potential in the treatment of non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 81(6), 1011-1018.

Nguyen, L. T., & Kim, M. H. (2019). Targeted therapies in cancer treatment: Advances and challenges. Oncogene Reviews, 41(12), 2493-2502.
Market Analysis Reports
List of Reports Available for Roblitinib
Related Products
Ro 4929097  Ro 5126766  RO 8994  Robac AS 100  Robenacoxib  Robenidine hydrochloride  Robenidine hydrochloride  Robinetin  Robinin  Robinobiose  Robtein  Robtin  Roburic acid  Rocaglamide  Rocaglaol  Rocuronium  Rocuronium bromide  Rofecoxib  Roflumilast  Ro 48-8071 fumarate 


©  chemBlink. All rights reserved.  Content Disclaimer  |  About chemBlink  |  Contact